Median PFS for all patients at initial treatment for metastatic disease was 18.0 (17.0–19.0) months, while significant variances were identified within pathologic subtypes (HR+ vs. HER2+ vs. TNBC; 19 vs. 18 vs. 10 months, p < 0.001). The gene discussed is ERBB2; the disease is metastatic neoplasm.